Cargando…

Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial

INTRODUCTION: Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of coronavirus disease 19 (COVID-19) in health personnel exposed to p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas-Serrano, Jorge, Portillo-Vásquez, Angelica Margarita, Thirion-Romero, Ireri, Vázquez-Pérez, Joel, Mejía-Nepomuceno, Fidencio, Ramírez-Venegas, Alejandra, Pérez-Kawabe, Karla Midori, Pérez-Padilla, Rogelio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827445/
https://www.ncbi.nlm.nih.gov/pubmed/35139097
http://dx.doi.org/10.1371/journal.pone.0261980
_version_ 1784647629901135872
author Rojas-Serrano, Jorge
Portillo-Vásquez, Angelica Margarita
Thirion-Romero, Ireri
Vázquez-Pérez, Joel
Mejía-Nepomuceno, Fidencio
Ramírez-Venegas, Alejandra
Pérez-Kawabe, Karla Midori
Pérez-Padilla, Rogelio
author_facet Rojas-Serrano, Jorge
Portillo-Vásquez, Angelica Margarita
Thirion-Romero, Ireri
Vázquez-Pérez, Joel
Mejía-Nepomuceno, Fidencio
Ramírez-Venegas, Alejandra
Pérez-Kawabe, Karla Midori
Pérez-Padilla, Rogelio
author_sort Rojas-Serrano, Jorge
collection PubMed
description INTRODUCTION: Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of coronavirus disease 19 (COVID-19) in health personnel exposed to patients infected by SARS-CoV-2. METHODS: Double-blind randomized, placebo-controlled single center clinical trial. Included subjects were health care workers caring for severe COVID-19 patients. Main outcome was time to symptomatic SARS-CoV-2 infection. RESULTS: 127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included in the trial. 62 assigned to HCQ and 65 to placebo. One subject (1.6%) in the HCQ group and 6 (9.2%) subjects in the placebo group developed COVID-19 (Log-Rank test p = 0.07). No severe COVID-19 cases were observed. The study was suspended because of a refusal to participate and losses to follow up after several trials reported lack of effectiveness of hydroxychloroquine in hospitalized patients with COVID-19. CONCLUSION: The effect size of hydroxychloroquine was higher than placebo for COVID-19 symptomatic infection in health personnel, although this was not statistically significant. The trial is underpowered due to the failure to complete the estimated sample size.
format Online
Article
Text
id pubmed-8827445
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-88274452022-02-10 Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial Rojas-Serrano, Jorge Portillo-Vásquez, Angelica Margarita Thirion-Romero, Ireri Vázquez-Pérez, Joel Mejía-Nepomuceno, Fidencio Ramírez-Venegas, Alejandra Pérez-Kawabe, Karla Midori Pérez-Padilla, Rogelio PLoS One Research Article INTRODUCTION: Health care workers are at high risk of being infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our aim is to evaluate the efficacy and safety of hydroxychloroquine (HCQ) for prophylaxis of coronavirus disease 19 (COVID-19) in health personnel exposed to patients infected by SARS-CoV-2. METHODS: Double-blind randomized, placebo-controlled single center clinical trial. Included subjects were health care workers caring for severe COVID-19 patients. Main outcome was time to symptomatic SARS-CoV-2 infection. RESULTS: 127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included in the trial. 62 assigned to HCQ and 65 to placebo. One subject (1.6%) in the HCQ group and 6 (9.2%) subjects in the placebo group developed COVID-19 (Log-Rank test p = 0.07). No severe COVID-19 cases were observed. The study was suspended because of a refusal to participate and losses to follow up after several trials reported lack of effectiveness of hydroxychloroquine in hospitalized patients with COVID-19. CONCLUSION: The effect size of hydroxychloroquine was higher than placebo for COVID-19 symptomatic infection in health personnel, although this was not statistically significant. The trial is underpowered due to the failure to complete the estimated sample size. Public Library of Science 2022-02-09 /pmc/articles/PMC8827445/ /pubmed/35139097 http://dx.doi.org/10.1371/journal.pone.0261980 Text en © 2022 Rojas-Serrano et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rojas-Serrano, Jorge
Portillo-Vásquez, Angelica Margarita
Thirion-Romero, Ireri
Vázquez-Pérez, Joel
Mejía-Nepomuceno, Fidencio
Ramírez-Venegas, Alejandra
Pérez-Kawabe, Karla Midori
Pérez-Padilla, Rogelio
Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial
title Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial
title_full Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial
title_fullStr Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial
title_full_unstemmed Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial
title_short Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial
title_sort hydroxychloroquine for prophylaxis of covid-19 in health workers: a randomized clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827445/
https://www.ncbi.nlm.nih.gov/pubmed/35139097
http://dx.doi.org/10.1371/journal.pone.0261980
work_keys_str_mv AT rojasserranojorge hydroxychloroquineforprophylaxisofcovid19inhealthworkersarandomizedclinicaltrial
AT portillovasquezangelicamargarita hydroxychloroquineforprophylaxisofcovid19inhealthworkersarandomizedclinicaltrial
AT thirionromeroireri hydroxychloroquineforprophylaxisofcovid19inhealthworkersarandomizedclinicaltrial
AT vazquezperezjoel hydroxychloroquineforprophylaxisofcovid19inhealthworkersarandomizedclinicaltrial
AT mejianepomucenofidencio hydroxychloroquineforprophylaxisofcovid19inhealthworkersarandomizedclinicaltrial
AT ramirezvenegasalejandra hydroxychloroquineforprophylaxisofcovid19inhealthworkersarandomizedclinicaltrial
AT perezkawabekarlamidori hydroxychloroquineforprophylaxisofcovid19inhealthworkersarandomizedclinicaltrial
AT perezpadillarogelio hydroxychloroquineforprophylaxisofcovid19inhealthworkersarandomizedclinicaltrial